Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 5
Submit an article Journal homepage
35
Views
1
CrossRef citations to date
0
Altmetric
Review

Coronary heart disease prevention in menopausal women

Daniel SchneiderGeorge Washington University 2150 Pennsylvania Ave NW, Washington, DC 20037USATel: +1 202 741 2323; Fax: +1 202 741 2324;E-mail: [email protected]
&
Judith HsiaGeorge Washington University 2150 Pennsylvania Ave NW, Washington, DC 20037USATel: +1 202 741 2323; Fax: +1 202 741 2324;E-mail: [email protected]
Pages 695-705 | Published online: 10 May 2005

Bibliography

  • MCKINLAY SM, BIFANO NL, MCKINLAY JB: Smoking and age at menopause in women. iAnn. Intern. Med. i (1985) 103(3):350–356.
  • LONGCOPE C: The endocrinology of the menopause. In: iTreatment of the Postmenopausal Woman. i Lobo RA (Ed.), Raven Press, New York, NY (1993):47.
  • JENSEN J, NILAS L, CHRISTIANSEN C: Influence of menopause on serum lipids and lipoproteins. iMaturitas i (1990) 12(0321–331.
  • STEVENSON JC, CROOK D, GODSLAND IF: Influence of age and menopause on serum lipids and lipoprotein in healthy women. iAtherosclerosis i (1993) 98(1):83–90.
  • CAMPOS H, MCNAMARA JR, WILSON PW, ORDOVAS JM, SCHAEFER EJ: Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. ./. iEndocrine]. Metab. i (1988) 67(1):30–35.
  • ABBEY M, OWEN A, SUZAKAWA M, ROACH P, NESTEL PJ: Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. iMaturitas i (1999) 33(3):259–269.
  • GORDON T, KANNEL WB, HJORTLAND MC, MCNAMARA PM: Menopause and coronary heart disease: The Framingham Study. iAnn. Intern. Med. i (1978) 89(2):157–161.
  • GORDON DJ, PROBSTFIELD JL, GARRISON RJ iet al: i High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. iCirculation i (1989) 79(1):8–15.
  • STAESSEN J, BULPITT CJ, FAGARD R, LUNEN P, AMERY A: The influence of menopause on blood pressure. ./. iHum. Hyperten. i (1989) 3(6):427–433.
  • VASAN RS, LARSON MG, LEIP EP iet al.: i Impact of high-normal blood pressure on the risk of cardiovascular disease. iN Eng]. J. Med. i (2001) 345 (18) :1291–1297.
  • REXRODE KM, CAREY VJ, HENNEKENS CH iet al.: i Abdominal adiposity and coronary heart disease in women. i"AMA i (1998) 280(20:1843–1848.
  • TOTH MJ, TCHERNOF A, SITES CK, POEHLMAN ET: Menopause-related changes in body fat distribution. iAnn. NY Acad. Sci. i (2000) 904:502–506.
  • STERNFELD B, WANG H, QUESENBERRY CP JR iet al: i Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. iAm. J. Epidemiel i (2004) 160(9):912–912.
  • HU FB, STAMPFER MJ, SOLOMON CG iet al.: i The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. iArch. Intern. Med. i (2001) 161(14):1717–1723.
  • LEE CC, KASA-VUBU JZ, SUPIANO MA: Androgenicity and obesity are independently associated with insulin sensitivity in postmenopausal women. iMetabolism i (2004) 53(4):507–512.
  • SOWERS M, DERBY C, JANNAUSCH ML, TORRENS JI, PASTERNAK R: Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. ./. Clin. iEndocrine]. Metab. i (2003) 88(10):4904–4910.
  • WALTON C, GODSLAND IF, PROUDLER AJ, WYNN V, STEVENSON JC: The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. iEur. I Clin. Invest. i (1993) 23(8):466–473.
  • MOSCA L, APPEL LJ, BENJAMIN EJ iet al.: i Evidence-based guidelines for cardiovascular disease prevention in women. iCirculation i (2004) 109(5):672–693.
  • ••Guidelines for cardiovascular diseaseprevention in women.
  • ASIAN PACIFIC COHORT STUDIES COLLABORATION: Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. iInt. J. Epidemiel i (2004) 33(4):751–758.
  • WILDMAN RP, GU D, REYNOLDS K DUAN X, HE J: Appropriate body mass index and waist circumference cutoffs for categorization of overweight and central adiposity among Chinese adults. iAm. J. Clin. Nutr. i (2004) 80(5):1129–1136.
  • CHOBANIAN AV, BAKRIS GL, BLACK HR iet al.: i The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. i"AMA i (2003) 289(19):2560–2572.
  • ••Current guidelines for management ofhypertension.
  • AMERICAN DIABETES ASSOCIATION: Diagnosis and classification of diabetes mellitus. iDiabetes Care i (2004) 27\(Suppl. 1):55–10.
  • STAMPFER MJ, HU FB MANSON JE, RIMM EB, WILLETT WC: Primary prevention of coronary heart disease in women through diet and lifestyle. iN Engl. J. Med. i (2000) 343(1):16–22.
  • KULLER LH, SIMKIN-SILVERMAN LR, WING R, MEILAHN EN, IVES DG: Women's Healthy Lifestyle Project: A randomized clinical trial: results at 54 months. iCirculation i (2001) 103(1):32–37.
  • PEPINE CJ, COOPER-DEHOFF RM: Cardiovascular therapies and risk for development of diabetes. iJ. Am. Coll. Cardiol i (2004) 44(3):509–512.
  • MARGOLIS KL, BONDS DE, RODABOUGH RJ, WOMEN'S HEALTH INITIATIVE INVESTIGATORS: Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. iDiabetologia i (2004) 47(7):1175–1187.
  • KNOWLER WC, BARRETT-CONNOR E, FOWLER SE iet al.: i Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. iN Engl. I Med. i (2002) 346(6):393–403.
  • DAHLOF B, DEVEREUX RB, KJELDSEN SE iet al: i Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. iLancet i (2002) 359(9311):995–1003.
  • YUSUF S, GERSTEIN H, HOOGWERF B iet al: i Ramipril and the development of diabetes. iJAMA i (2001) 286(15):1882–1885.
  • FREEMAN DJ, NORRIE J, SATTAR N iet al.: i Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. iCirculation i (2001) 103(3):357–362.
  • SEVER PS, DAHLF B, POULTER NR iet al. i Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. iLancet i (2003) 361(9364):1149–1158.
  • HANSSON L, ZANCHETTI A, CARRUTHERS SG iet al: i Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. iLancet i (1998) 351(9118):1755–1762.
  • KJELDSEN SE, WARNOLD I, HANSSON L, HOT STUDY GROUP: Influence of gender on prevention of myocardial infarction by antihypertensives and acetylsalicylic acid: the HOT study. iCend. Speed: Med. i (2000) 3(8):35–38.
  • DE GAETANO G, COLLABORATIVE GROUP OF THE PRIMARY PREVENTION PROJECT: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. iLancet i (2001) 357(9250):89–95.
  • RIDKER PM, COOK NR, LEE I-M iet al: iA randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. iN Engl. I Med. i (2005) 352(13):1293–1304.
  • AMERY A, BIRKENHAGER W, BRIXKO P iet al.: i Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. iLancet i (1985) 1(8442):1349–1354.
  • SHEP COOPERATIVE RESEARCH GROUP: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). iJAMA i (1991) 265(24):3255–3264.
  • ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). iJAMA i (2002) 288(23):2981–2997.
  • DEVEREUX RB, DAHLOF B, KJELDSEN SE iet al.: i Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. iAnn. Intern. Med. i (2003) 139(3):169–177.
  • BELLA JN, PALMIERI V, WACHTELL K iet al.: i Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. iJ. Hum. Hypertens. i (2004) 18(6):411–416.
  • LAW MR, WALD NJ, MORRIS JK, JORDAN RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. iBr. Med. J. i (2003) 326(7404):1427–1431.
  • DEZII CM: A retrospective study of persistence with single-pill combination therapy versus concurrent two-pill therapy in patients with hypertension. iManag. Care i (2000) 9\(Suppl. 9):2–6.
  • CLEARFIELD M, DOWNS JR, WEIS S iet al: i Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. iWomens Health Cend. Based Med. i (2001) 10(10):971–981.
  • COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN iet al: i Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. iLancet i (2004) 364(9435):685–696.
  • FRICK MH, ELO O, HAAPA K iet al: i Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. iN Engl. I Med. i (1987) 317(20):1237–1245.
  • GOLDBERG AC: A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. iAm. Cardiol i (2004) 94(19131):121–124.
  • UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). iLancet i (1998) 352(9131):837–853.
  • GAEDE P, VEDEL P, LARSEN N, JENSEN GV, PARVING HH, PEDERSEN O: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. iN Engl. J. Med. i (2003) 348(5):383–393.
  • GRODSTEIN F, CLARKSON TB, MANS ON JE: Understanding the divergent data on postmenopausal hormone therapy. iN Engl. I Med. i (2003) 348(7):645–650.
  • ROSSOUW JE, ANDERSON GL, PRENTICE RL iet al.: i Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. iJAMA i (2002) 288(3):321–333.
  • MANSON JE, HSIA J, JOHNSON KC iet al: i Estrogen plus progestin and the risk of coronary heart disease. iN Engl. I Med. i (2003) 349(6):523–534.
  • CHLEBOWSKI RT, HENDRIX SL, LANGER RD iet al.: i Influence of estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. iJAMA i (2003) 289(24):3243–3253.
  • WASSERTHEIL-SMOLLER S, HENDRIX S, LIMACHER M iet al.: i Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative:a randomized trial. iJAMA i (2003) 289(20):2673–2684.
  • CUSHMAN M, KULLER LH, PRENTICE R iet al.: i Estrogen plus progestin and risk of venous thrombosis. iJAMA i (2004) 292(13):1573–1580.
  • SHUMAKER SA, LEGAULT C, RAPP S iet al.: i Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. i"AMA i (2003) 289(20):2651–2662.
  • CAULEY JA, ROBBINS J, CHEN Z iet al: i Effects of estrogen plus progestin on the risk for fracture and bone mineral density: the Women's Health Initiative randomized trial. iJAMA i (2003) 290(13):1729–1738.
  • CHLEBOWSKI RT, WACTAWSKI-WENDE J, RITENBAUGH C iet al: i Estrogen plus progestin and colorectal cancer in postmenopausal women. iN Engl..1. Med. i (2004) 350(10):991–1004.
  • ANDERSON GL, LIMACHER M, ASSAF AR iet al: i Effects of conjugated equine estrogen on postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. iJAMA i (2004) 291(14):1701–1712.
  • ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. iBr. Med. J. i (2002) 324(7329):71–86.
  • CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). iLancet (1996) i 348(9038):1329–1339.
  • HJALMARSON A: International B-blocker review in acute and postmyocardial infarction. iAm. J. Cardiol i (1988) 61(3):26B-29B.
  • SHEKELLE PG, RICH MW, MORTON SC iet al: i Efficacy of angiotensin-converting enzyme inhibitors and B-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. I iAm. Coll. Cardiol i (2003) 41(9):1529–1538.
  • GHALI JK, PIICIA IL, GOTTLIEB SS, DEEDWANIA PC, WIKSTRAND JC: Metoprolol CR/XL in female patients with heart failure: analysis of the experience in the Metoprolol Controlled Release Randomized Intervention Trial in Heart Failure (MERIT-HF). iCirculation i (2002) 105(13):1585–1591.
  • YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. iN. Engl. J. Med. i (2000) 342(3):145–153.
  • LONN E, ROCCAFORTE R, YI Q iet al: i Effect of long-term therapy with ramipril in high-risk women. I iAm. Coll. Cardiol i (2002) 40(4):693–702.
  • FOX KM, EUROPEAN TRIAL ON REDUCTION OF CARDIAC EVENTS WITH PERINDOPRIL IN STABLE CORONARY ARTERY DISEASE INVESTIGATORS: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). iLancet i (2003) 362(9386):782–788.
  • BRAUNWALD E, DOMANSKI MJ, FOWLER SE iet al.: i Angiotensin-converting-enzyme inhibition in stable coronary artery disease. iN Engl. I Med. i (2004) 351(20):2058–2068.
  • JULIUS S, KJELDSEN SE, WEBER M iet al: i Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. iLancet i (2004) 363(9426):2022–2031.
  • MIETTINEN TA, PYORALA K, OLSSON AG iet al: i Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). iCirculation i (1997) 96(12):4211–4218.
  • LEWIS SJ, SACKS FM, MITCHELL JS iet al: i Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. iJ. Am. Coll. Cardiol i (1998) 32(1):140–146.
  • THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. iN Engl. I Med. i (1998) 339(19):1349–1357.
  • HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. iLancet i (2002) 360(9326):7–22.
  • RUBINS HB, ROBINS SJ, COLLINS D iet al.: i Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. iN Engl. J. Med. i (1999) 341(6):410–418.
  • CANNER PL, BERGE KG, WENGER NK iet al.: i Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. I iAm. Coll. Cardiol i (1986) 8(6):1245–1255.
  • GRUNDY SM, CLEEMAN JI, MERZ CN iet al: i Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. iCirculation i (2004) 110(2):227–239.
  • ••Update to lipid management guidelines.
  • GRUNDY SM, BECKER D, CLARK LT iet al.: i Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. iCirculation i (2002) 106(25):3143–3421.
  • HULLEY S, GRADY D, BUSH T iet al: i Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. iJAMA i (1998) 280(7):605–613.
  • CHERRY N, GILMOUR K, HANNAFORD P iet al: i ESPRIT TEAM: Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo-controlled trial. iLancet i (2002) 360(9350):2001–2008.
  • CLARKE SC, KELLEHER J, LLOYD-JONES H, SLACK M, SCHOFIEL PM: A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. iBIOC i (2002) 109(9):1056–1062.

Websites

  • http://www.americanheartorg/ downloadable/heart/ 1075705991817FS10WM04.pdf Accessed 3/15/05
  • http://www.cdc.gov/nchs/data/nhanes/ overweight.pdf accessed 12/17/04 Accessed 12/17/04
  • http://www.health.gov/dietaryguidelines/ dga 192005/document/html/ executivesummary.htm Accessed 3/15/05

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.